ARDD 2026 talk: DNA methylation assay in a tirzepatide trial
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description says a talk at ARDD 2026 presented a large DNA methylation dataset and a longitudinal tirzepatide trial, where one methylation assay tracked biological age, surrogate biomarkers and future disease risk. [1]
The description says a single DNA methylation assay can serve as a broad trial endpoint, tracking biological age, surrogate biomarkers and future disease risk in a tirzepatide trial. [1]
The talk is attributed to Kirsten Seale of TruDiagnostic at the 13th Aging Research and Drug Discovery Meeting and links a large-scale DNA methylation asset with epigenetic insights from a longitudinal trial. [1]
The description presents ARDD as a longevity biotechnology conference founded in 2014 that held its North American debut in Boston on October 1-3, 2026. [1]
Tirzepatide trial and methylation assay
The description attributes to Kirsten Seale of TruDiagnostic a talk at the 13th Aging Research and Drug Discovery Meeting. The stated takeaway is that a single DNA methylation assay can serve as a broad trial endpoint. It is said to track biological age, surrogate biomarkers and future disease risk, as shown in a tirzepatide trial described as longitudinal. The description gives no participant numbers, dosing, duration or comparison group. [1]
Large methylation asset and conference setting
The talk title links a large-scale DNA methylation asset with epigenetic insights from the trial. The description also describes ARDD as a conference for longevity biotechnology that brings together researchers, pharmaceutical executives, regulators, entrepreneurs and investors. It says ARDD was founded by Alex Zhavoronkov in 2014 and made its North American debut in Boston on October 1-3, 2026. These are conference details, not study results. [1]
What the description does not establish
The description reports a claimed takeaway but no measured values, effect sizes or statistical uncertainty. It does not say whether the methylation findings reflect an effect of tirzepatide or another factor, so no causal or clinical benefit can be inferred. Whether the assay is validated as a trial endpoint is also not stated. The description is the only material summarised here. [1]
Context & limits
Only the video description was available; the video and transcript were not reviewed. The description gives no participant numbers, dosing, duration, comparison group, measured values or uncertainty, and does not establish causality or clinical benefit.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
A single DNA methylation assay can serve
From Infrastructure to Insight
ARDD made its North American debut in
About this video
Creator description · original textText language: English
ARDD · 16 min · Source published: 2026-10-21
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.